Endo | 97,393 followers on LinkedIn. Endo combined with Mallinckrodt Pharmaceuticals in 2025 to better serve customers and improve outcomes for the patients we support. From this union, we established two focused, standalone companies: – Keenova Therapeutics, a branded therapeutics business – Par Health, a generics and sterile injectables business To learn more, follow Keenova and Par Health on LinkedIn and visit keenova.com and parhealth.com.